Emerging in the field of obesity treatment, retatrutide presents a distinct method. Unlike many current medications, retatrutide operates as a dual agonist, concurrently affecting both glucagon-like peptide-1 (GLP-1) and glucose-responsive insulinotropic substance (GIP) binding sites. This dual activation fosters various advantageous effects, such